Consultation record

Submissions accepted — page 22

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

735 documents · page 22 of 25

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-POORLY-RETAI/015	Draft standard CEI-MS-19: Purity determination for peptides not…	Dr Evander Whitmarsh-Obi	Quantitative claims are reproduced without the method that produced them
DRAFT-POORLY-RETAI/016	Draft standard CEI-MS-19: Purity determination for peptides not…	Stellan Cholmondeley-Ade	A determination does not record the version of the standard it was made under
DRAFT-PHOTOSTABILI/004	Draft standard CEI-MS-20: Photostability assessment of…	Dr Xenia Nyquist-Obiora	A cycle is not defined and the rate of thaw is not controlled
DRAFT-DUAL-VS-SING/002	Draft synthesis: Dual and triple incretin receptor agonists compared…	Thaddeus Isaksen-Balogun	The timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-DUAL-VS-SING/007	Draft synthesis: Dual and triple incretin receptor agonists compared…	Dr Kolawole Isaksen-Balogun	A funnel plot is presented for a set too small to interpret it
DRAFT-INCRETIN-CAR/002	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Odalys Thorsby-Nakamura	Results at materially different follow-up durations are pooled
DRAFT-INCRETIN-CAR/008	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Kolawole Isaksen-Balogun	Studies using different outcome definitions are pooled into one estimate
DRAFT-INCRETIN-CAR/009	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Zdenka Ximenes	Efficacy outcomes are rated for certainty and harms are not
DRAFT-INCRETIN-CAR/010	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Eamon Immelmann	Analytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-INCRETIN-CAR/011	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Theodora Ingelbrecht	Doses differing several-fold are pooled without examining dose-response
DRAFT-INCRETIN-CAR/013	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Oisín Rautavaara	The timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-GASTROINTEST/003	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Evander Whitmarsh-Obi	Analytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-GASTROINTEST/005	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Adaeze Underhill-Okafor	Attrition is assessed in the risk-of-bias domains and not reported as a number
DRAFT-GASTROINTEST/007	Draft synthesis: Gastrointestinal adverse events with incretin…	Thaddeus Isaksen-Balogun	Studies using different outcome definitions are pooled into one estimate
DRAFT-GASTROINTEST/008	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Kolawole Isaksen-Balogun	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-GASTROINTEST/009	Draft synthesis: Gastrointestinal adverse events with incretin…	Anselm Mountstephen	The search strategy as published cannot be re-run
DRAFT-GASTROINTEST/011	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Jozef Brandvold-Achterberg	Absence of evidence is presented in a form a reader will take as negative evidence
DRAFT-ORAL-VS-INJE/002	Draft synthesis: Oral compared with injectable presentations of…	Dr Melisande Kirkpatrick-Ola	Risk-of-bias judgements are reported as an overall rating without the domains
DRAFT-ORAL-VS-INJE/006	Draft synthesis: Oral compared with injectable presentations of…	Dr Marisol Dunmore-Ekpo	Registered trials that never reported are not counted anywhere in the review
DRAFT-ORAL-VS-INJE/007	Draft synthesis: Oral compared with injectable presentations of…	Dr Quentin Zimmerthal	Analytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-ORAL-VS-INJE/008	Draft synthesis: Oral compared with injectable presentations of…	Dr Kolawole Isaksen-Balogun	Studies using different outcome definitions are pooled into one estimate
DRAFT-ORAL-VS-INJE/009	Draft synthesis: Oral compared with injectable presentations of…	Dr Melisande Thorsby-Nakamura	Quantitative claims are reproduced without the method that produced them
DRAFT-ORAL-VS-INJE/013	Draft synthesis: Oral compared with injectable presentations of…	Eamon Sandringham-Adu	The search strategy as published cannot be re-run
DRAFT-ORAL-VS-INJE/014	Draft synthesis: Oral compared with injectable presentations of…	Dr Lorcan Zaleski-Mbeki	Efficacy outcomes are rated for certainty and harms are not
DRAFT-ORAL-VS-INJE/015	Draft synthesis: Oral compared with injectable presentations of…	Dr Oisín Rautavaara	A funnel plot is presented for a set too small to interpret it
DRAFT-RENAL-OUTCOM/006	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Oisín Rautavaara	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-RENAL-OUTCOM/010	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Liesbeth Zaleski-Mbeki	Doses differing several-fold are pooled without examining dose-response
DRAFT-RENAL-OUTCOM/011	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Melisande Kirkpatrick-Ola	Risk-of-bias judgements are reported as an overall rating without the domains
DRAFT-SLEEP-APNOEA/001	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Kolawole Isaksen-Balogun	The timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-SLEEP-APNOEA/003	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Adaeze Underhill-Okafor	Results at materially different follow-up durations are pooled

page 22 of 25